Clinical trials: Acute Non-ST Elevation Myocardial Infarction
Obesity /Overweight, Acute Myocardial Infarction (STEMI/ NSTEMI)
Diet Therapy Versus Prescriptive Educational Group Intervention in Overweight / Obese Patients at First Episode of AMI: a Randomized Controlled Trial
Results after interventions on lifestyle in the secondary prevention of ischemic heart disease are not always consistent, and the Guidelines multidisciplinary measures aren't easily achievable.
- Trial name
- NCT02323802
- Testing
- educational group intervention, prescriptive diet
- Where
- 2 sites in Italy
- Volunteers
- 90 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Myocardial Infarction, Myocardial Ischemia
Time for a Paradigm Shift: STEMI/NSTEMI to OMI/NOMI ?
The current ST-segment elevation (STEMI)/non-STEMI treatment paradigm misses nearly one fourth of acute coronary occlusions (ACO) that needs immediately reperfusion.
- Trial name
- DIFOCCULT-2 (NCT05705102)
- Testing
- Coronary intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 2,500 people
- Sponsor
- Marmara University
Myocardial Ischemia
Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes
MERLIN-TIMI 36 is a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of ranolazine during acute and long-term treatment in approximately…
- Trial name
- NCT00099788
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 6,560 people
- Sponsor
- Gilead Sciences
Myocardial Infarction
Studying the Effectiveness of Early Invasive Treatment in Elderly Patients With High-risk Non-ST-segment Elevation Acute Coronary Syndrome.
The goal of this is observational study is to compare about MACE events and predisposing factors related to MACE events in elderly patients with high-risk non-ST acute coronary syndromes receiving early versus late invasive…
- Trial name
- NCT06486233
- Where
- Vietnam
- Volunteers
- 385 people
- Sponsor
- Gia Dinh People Hospital
Myocardial Infarction
Utility of Residual Syntax Score to Predict Outcome After Acute Myocardial Infarction
The aim of this study is to evaluate the utility of residual syntax score after PCI of the culprit vessel for patients with AMI (STEMI or NSTEMI) to predict 6-months clinical outcomes.
- Trial name
- NCT05392777
- Testing
- Residual syntax score
- Where
- Egypt
- Volunteers
- 490 people
- Sponsor
- Cairo University
Acute Coronary Syndrome, Unstable Angina
Acute Coronary Syndrome Sri Lanka Audit Project
ACSSLAP is the first island wide audit project in Sri Lanka on ACS.
- Conditions
- Acute Coronary Syndrome, Unstable Angina, Non ST Elevation Myocardial Infarction, ST Elevation Myocardial Infarction
- Trial name
- ACSSLAP (NCT02893280)
- Testing
- aspirin, clopidogrel, statin, enoxaparin, streptokinase
- Where
- Sri Lanka
- Sponsor
- University of Colombo
Acute Coronary Syndromes (ACS), Ventricular Tachycardia (VT)
Analysis of Life-threatening ARrhythMias After Acute Coronary Syndrome
Patients admitted with an acute coronary syndrome (ACS) are at increased risk of malignant cardiac arrhythmias (MA), such as sustained ventricular tachycardia and ventricular fibrillation.
- Conditions
- Acute Coronary Syndromes (ACS), Ventricular Tachycardia (VT), Ventricular Fibrillation, Pulseless Electrical Activity
- Trial name
- ALARM-ACS (NCT07824050)
- Where
- Netherlands
- Volunteers
- 2,775 people
- Sponsor
- Catharina Ziekenhuis Eindhoven
Acute Coronary Syndrome (ACS)
Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL
CTQJ230A1US13 is a randomized, double-blind, placebo-controlled, multicenter phase IIIb study designed to evaluate the efficacy, safety, tolerability, and coronary plaque effects of early pelacarsen (TQJ230) initiation in…
- Trial name
- NCT07625306
- Testing
- Pelacarsen
- Sponsor
- Novartis Pharmaceuticals
Coronary Artery Diseases
BIOFLOW-III UK Satellite Registry Orsiro Stent System
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). 500 subjects will be enrolled in this registry.
- Trial name
- NCT02257710
- Testing
- Orsiro
- Where
- 4 sites in United Kingdom
- Volunteers
- 500 people
- Sponsor
- Biotronik UK Ltd.
Myocardial Infarction, Myocardial Ischemia
Time for a Diagnostic Paradigm Shift From STEMI/NSTEMI to OMI/NOMI
The investigators hypothesize that occlusion myocardial infarction(MI)/non-occlusion MI approach to MI treatment will better predict acute coronary occlusion on coronary angiography, better limit infarct size, better preserve…
- Conditions
- Myocardial Infarction, Myocardial Ischemia, Acute Coronary Syndrome, Diagnosis
- Trial name
- DIFOCCULT-3 (NCT06570759)
- Testing
- Early intervention for OMI, Standard early intervention for STEMI, Standard delayed intervention for NSTEMI
- Where
- 18 sites in Turkey (Türkiye)
- Volunteers
- 6,000 people
- Sponsor
- Başakşehir Çam & Sakura City Hospital
Effect of Diabetes on Long Term Excess Mortality Following Acute Myocardial Infarction
Long Term Excess Mortality of Acute Myocardial Infarction in Patients With and Without Diabetes: A Population-based Cohort Study
Diabetes is key risk factor for death following acute myocardial infarction. However, the long-term excess risk of death associated with diabetes following acute myocardial infarction not known.
- Trial name
- NCT02591576
- Volunteers
- 700,000 people
- Sponsor
- University of Leeds
Atrial Fibrillation
Artificial Intelligence Models to Predict Clinically Relevant Cardiovascular Outcomes
Atrial fibrillation (AF) is a frequent and clinically relevant problem among the events that may occur during the hospitalization period in patients with cardiovascular disease.
- Trial name
- PERCARD (NCT06847100)
- Testing
- Blood withdrawal
- Where
- 4 sites in Finland, Germany and 1 more
- Volunteers
- 273 people
- Sponsor
- Centro Cardiologico Monzino
STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)
Intensive Cholesterol-Lowering Within 24 Hours of PCI Perioperative Period
This project team is conducting a multicenter randomized controlled study, aiming to administer PCSK9 inhibitors subcutaneously as early as possible within 24 hours during the perioperative period of AMI (included <24h STEMI and…
- Trial name
- INCLINE-AMI (NCT07290699)
- Testing
- Recaticimab
- Volunteers
- 2,442 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Cardiovascular; Attack
Very Early Versus Delayed Angiography +/- Intervention on Outcomes in Patients With NSTEMI
Prospective, open, multicentre, randomised controlled trial in patients with higher risk non-ST elevation myocardial infarction acute coronary syndrome
- Trial name
- RapidNSTEMI (NCT03707314)
- Testing
- Angiography with follow-on revascularisation if indicated
- Where
- United Kingdom
- Volunteers
- 425 people
- Sponsor
- University Hospitals, Leicester
Microvascular Obstruction (MVO), Multivessel Coronary Artery Disease
For Patients With Myocardial Infarction and Multiple Vessel: Testing if Ultrasound (UFR) Can Guide All Needed Treatment in One Procedure, Avoiding a Return Hospital Visit for a Second Operation.
Brief Summary The Purpose of the Study : The purpose of this study is to find a safe and reliable "one-stop" solution for treating heart attack patients who have multiple blocked arteries.
- Conditions
- Microvascular Obstruction (MVO), Multivessel Coronary Artery Disease, ACS (Acute Coronary Syndrome), ST Elevation Myocardial Infarction (STEMI)
- Trial name
- ACT-EVOLVE (NCT07264881)
- Testing
- IVUS-based Fractional Flow Reserve (UFR), Invasive Coronary Physiology Measurement (FFR/RFR/IMR), Cardiac Magnetic Resonance (CMR)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Beijing Anzhen Hospital
Non ST Segment Elevation Myocardial Infarction, Unstable Angina
Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation
This non-inferiority study aims at comparing Versa® to the reference enoxaparin (Clexane®, Sanofi-Aventis) in patients with high-risk unstable angina and NSTEMI.
- Trial name
- VECOR (NCT01356992)
- Testing
- Enoxaparin
- Where
- 5 sites in Brazil
- Volunteers
- 62 people
- Sponsor
- Eurofarma Laboratorios S.A.
Cost Sharing, Acute Coronary Syndrome
Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study
Current patterns of P2Y12 receptor inhibitor use provide an excellent opportunity to test the impact of copayment reduction on clinician choice of medication, patient adherence, and clinical outcomes.
- Trial name
- ARTEMIS (NCT02406677)
- Testing
- Study voucher card
- Where
- 272 sites in United States, Puerto Rico
- Volunteers
- 11,001 people
- Sponsor
- AstraZeneca
Acute Myocardial Infarction
Study to Assess the Safety and Cardiovascular Effects of Autologous Adipose-Derived Stromal Cells Implantation In Patients During the Acute Recovery Phase of ST-Elevation Myocardial Infarction
The intent of this clinical study is to answer the questions: 1) Is the proposed treatment safe? and 2) Is treatment effective in improving cardiac function and clinical outcomes?
- Trial name
- Acute MI (NCT01974128)
- Testing
- ASC isolation and implantation
- Where
- United States
- Sponsor
- Ageless Regenerative Institute
Coronary Artery Disease, Stable Angina
Validation of the MedHub AutocathFFR Software Device for Non-Invasive Fractional Flow Reserve (FFR)
This observational study evaluated how well the AutocathFFR software measures fractional flow reserve (FFR) from coronary angiogram images.
- Conditions
- Coronary Artery Disease, Stable Angina, Unstable Angina, Non-ST-Elevation Myocardial Infarction
- Trial name
- NCT07763769
- Testing
- MedHub AutocathFFR
- Where
- 4 sites in United States
- Volunteers
- 277 people
- Sponsor
- Medhub Ltd.
Myocardial Infarction, Coronary Disease
Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome
The purpose of this study is to determine which of these anti-clotting medications, abciximab plus unfractionated heparin or bivalirudin, is more effective to prevent thrombotic and bleeding complications in patients suffering…
- Trial name
- ISAR-REACT-4 (NCT00373451)
- Testing
- Abciximab + UFH, Bivalirudin, Heparin
- Where
- 9 sites in Germany, Italy
- Volunteers
- 1,721 people
- Sponsor
- Deutsches Herzzentrum Muenchen